This SDS packet was issued with item:

071437359

N/A



Revision date 26-Mar-2023

Version 2

Page 1 / 13

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name	Rocuronium Bromide Injection (Hospira Inc.)
Product Code(s)	PZ03127
Trade Name:	Rocuronium Bromide Injection
Chemical Family:	Not determined

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use

Pharmaceutical product

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company 275 North Field Drive Lake Forest, Illinois 60045 1-800-879-3477 Hospira UK Limited Horizon Honey Lane Hurley Maidenhead, SL6 6RJ United Kingdom

E-mail address

pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone

Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: Not classified as hazardous according to Regulation (EC) 1272/2008 and/or other applicable regulations.

<u>2.2. Label elements</u> Signal word	Not Classified
Hazard statements	Not classified in accordance with international standards for workplace safety.
<u>2.3. Other hazards</u> Other hazards	An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).
Note:	This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Chemical name	Weight-%	REACH	EC No	Classification	Specific	M-Factor	M-Factor
	-	Registration		according to	concentration		(long-term)
		Number		Regulation	limit (SCL)		
				(EC) No.	. ,		
				1272/2008			
				[CLP]			
Sodium hydroxide	**	-	215-185-5	Skin Corr.1A	Eye Irrit. 2 ::	No data	No data
(CAS #: 1310-73-2)				(H314)	0.5%<=C<2%	available	available
(,					Skin Corr. 1A ::		
					C>=5%		
					Skin Corr. 1B ::		
					2%<=C<5%		
					Skin Irrit. 2 ::		
					0.5%<=C<2%		
+ ACETIC ACID	**		200-580-7	Skin Corr. 1A	Eye Irrit. 2 ::	No data	No data
(CAS #: 64-19-7)				(H314)	10%<=C<25%	available	available
					Skin Corr. 1A ::	available	available
				(H226)	C>=90%		
				(11220)	Skin Corr. 1B ::		
					25%<=C<90%		
					Skin Irrit. 2 ::		
					10%<=C<25%		
IonHazardous							
Chemical name	Weight-%	REACH	EC No	Classification	Specific	M-Factor	M-Factor
	Ū	Registration		according to	concentration		(long-term)
		Number		Regulation	limit (SCL)		
				(EC) No.	. ,		
				1272/2008			
				[CLP]			
Water	*	-	231-791-2	Not classified	Not Listed	No data	No data
(CAS #: 7732-18-5)				as hazardous		available	available
SODIUM CHLORIDE	*	-	231-598-3	Not classified	Not Listed	No data	No data
(CAS #: 7647-14-5)				as hazardous		available	available
Rocuronium Bromide	1		Not Listed	Not classified	Not Listed	No data	No data
(CAS #:	-			as hazardous		available	available
119302-91-9)							
Sodium Acetate	*		204-823-8	Not classified	Not Listed	No data	No data
			_0.0_00				

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate No information available

(CAS #: 127-09-3)

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4	Inhalation LC50 - 4	Inhalation LC50 - 4
			hour - dust/mist -	hour - vapor - mg/L	hour - gas - ppm
			mg/L		
Water	89838.9	No data available	No data available	No data available	No data available
7732-18-5					
SODIUM CHLORIDE	3000	10000	No data available	No data available	No data available

as hazardous

available

available

Product Name Rocuronium Bromide Injection (Hospira Inc.) Revision date 26-Mar-2023

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
7647-14-5					
Sodium Acetate 127-09-3	3530	10000	7.5	No data available	No data available
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available
+ ACETIC ACID 64-19-7	3310	1060	11.4	No data available	No data available

Additional information

* Proprietary

** to adjust pH

+ Substance with a Union workplace exposure limit

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for completeness.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water, also under the eyelids. If irritation occurs or persists, get medical attention.
Skin contact	Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
4.2. Most important symptoms and	effects, both acute and delayed
Most important symptoms and effects	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
4.3. Indication of any immediate me	edical attention and special treatment needed
Note to physicians	None.
Section 5: FIRE-FIGHTING M	EASURES
5.1. Extinguishing media	
Suitable Extinguishing Media	As for primary cause of fire.
5.2. Special hazards arising from the	e substance or mixture
Specific hazards arising from the chemical	Not applicable.
Hazardous combustion products	Formation of toxic gases is possible during heating or fire.
5.3. Advice for firefighters	

Use personal protection equipment.

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear.

Product Name Rocuronium Bromide Injection (Hospira Inc.) Revision date 26-Mar-2023

Special protective equipment for

fire-fighters

Section 6: ACCIDENTAL REL	EASE MEASURES
6.1. Personal precautions, protectiv	e equipment and emergency procedures
Personal precautions	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
For emergency responders	Use personal protection recommended in Section 8.
6.2. Environmental precautions	
Environmental precautions	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
6.3. Methods and material for conta	inment and cleaning up
Methods for containment Methods for cleaning up	Prevent further leakage or spillage if safe to do so. Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
Prevention of secondary hazards	Clean contaminated objects and areas thoroughly observing environmental regulations.
6.4. Reference to other sections	
Reference to other sections	See section 8 for more information. See section 13 for more information.
Section 7: HANDLING AND S	TORAGE

7.1. Precautions for safe handling

Advice on safe handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s)

Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Rocuronium Bromide

Pfizer OEL TWA-8 Hr: 20 µg/m³ SODIUM CHLORIDE Latvia

5 mg/m³

Product Name Rocuronium Bromide Injection (Hospira Inc.) Revision date 26-Mar-2023

Page 5 / 13 Version 2

Russia	
Russia Sodium Acetate	MAC: 5 mg/m ³
Russia	MAC: 10 mg/m ³
Sodium hydroxide	W/XO: TO Mg/M
ACGIH OEL (Ceiling)	2 mg/m ³
ACGIH TLV	Ceiling: 2 mg/m ³
Austria	2 mg/m ³
	STEL 4 mg/m ³
Bulgaria	2.0 mg/m ³
Czech Republic	1 mg/m ³ Ceiling: 2 mg/m ³
Denmark	Ceiling: 2 mg/m ³
Estonia	1 mg/m ³
Estonia	STEL: 2 mg/m ³
Finland	Ceiling: 2 mg/m ³
France	2 mg/m ³
Hungary	1 mg/m ³
	STEL: 2 mg/m ³
Ireland	STEL: 2 mg/m ³
Ceiling Limit Value	2 mg/m^3
Latvia Poland	0.5 mg/m³ STEL: 1 mg/m³
Folaliu	0.5 mg/m ³
Romania	1 mg/m ³
	STEL: 3 mg/m ³
Slovakia	2 mg/m ³
Spain	STEL: 2 mg/m ³
Switzerland	2 mg/m ³
	STEL: 2 mg/m ³
OSHA PEL	2 mg/m ³
United Kingdom	(vacated) Ceiling: 2 mg/m ³ STEL: 2 mg/m ³
+ ACETIC ACID	STEL. 2 mg/m
ACGIH TLV	STEL: 15 ppm
	10 ppm
Austria	10 ppm
	25 mg/m ³
	STEL 20 ppm
	STEL 50 mg/m ³
Bulgaria	STEL: 50 mg/m ³
	STEL: 20 ppm 25 mg/m³
	10 ppm
Czech Republic	25 mg/m ³
·	Ceiling: 50 mg/m ³
Denmark	10 ppm
	25 mg/m ³
Estonia	10 ppm
	25 mg/m ³
	STEL: 10 ppm STEL: 25 mg/m ³
European Union	50 mg/m ³ STEL; 20 ppm STEL
	25 mg/m ³ TWA; 10 ppm TWA
Finland	5 ppm
	13 mg/m ³
	STEL: 10 ppm
_	STEL: 25 mg/m ³
France	25 mg/m ³
Germany	10 ppm
	25 mg/m ³

25 mg/m³

Product Name Rocuronium Bromide Injection (Hospira Inc.) Revision date 26-Mar-2023 Page 6 / 13 Version 2

	Ceiling / Peak: 20 ppm
Germany	Ceiling / Peak: 50 mg/m ³ 10 ppm
	25 mg/m ³
Hungary	25 mg/m ³ STEL: 50 mg/m ³
Ireland	20 ppm
	50 mg/m³ STEL: 20 ppm
	STEL: 50 mg/m ³
Italy	25 ppm
	10 mg/m³ STEL: 50 mg/m³
	STEL: 20 ppm
Latvia	10 ppm 25 mg/m³
	STEL: 50 mg/m ³
	STEL: 20 ppm
Netherlands	25 mg/m ³
Poland	STEL: 50 mg/m ³ STEL: 50 mg/m ³
Folanu	25 mg/m ³
Romania	10 ppm
	25 mg/m ³
	STEL: 20 ppm
Russia	STEL: 50 mg/m ³ MAC: 5 mg/m ³
Rubbia	Skin
Slovakia	10 ppm
Spain	25 mg/m ³ 10 ppm
Spain	25 mg/m ³
	STEL: 20 ppm
.	STEL: 50 mg/m ³
Switzerland	10 ppm 25 mg/m³
	STEL: 20 ppm
	STEL: 50 mg/m ³
OSHA PEL	10 ppm
	25 mg/m ³
	(vacated) TWA: 10 ppm (vacated) TWA: 25 mg/m³
United Kingdom	TWA: 10 ppm
g	TWA: 25 mg/m ³
	STEL: 20 ppm
	STEL: 50 mg/m ³
Pfizer Occupational Exposure Band	3
(OEB) Statement:	The purpose of the Occupational Exposure Band (OEB) classification system is to separate
	substances into different Hazard categories when the available data are sufficient to do so,
	but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based
	upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.
8.2. Exposure controls	
Engineering controls	Engineering controls should be used as the primary means to control exposures. General
	room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Product Name Rocuronium Bromide Injection (Hospira Inc.) Revision date 26-Mar-2023

Environmental exposure controls	No information available.
Personal protective equipment	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.
Eye/face protection	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).
Hand protection	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).
Skin and body protection	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
Respiratory protection	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties	
Physical state	Liquid
Color	Colourless to Yellow-orange No information available.
Odor	
Odor threshold	No information available
Molecular formula	Mixture
Molecular weight	Mixture
Provident	Walara
Property	<u>Values</u> 3.8-4.2
pH Malting a sint / for a sing a sint	0.0
Melting point / freezing point	No data available
Boiling point / boiling range	Nie infermentien erwährte
Flash point	No information available
Evaporation rate	No data available
Flammability (solid, gas)	No data available
Flammability Limit in Air	NI 17 111
Upper flammability limit:	No data available
Lower flammability limit:	No data available
Vapor pressure	No data available
Vapor density	No data available
Relative density	No data available
Water solubility	Soluble
Solubility(ies)	No data available
Partition coefficient	No data available
Autoignition temperature	No data available
Decomposition temperature	No data available
Kinematic viscosity	No data available

Product Name Rocuronium Bromide Injection (Hospira Inc.) Revision date 26-Mar-2023

Dynamic viscosity
Particle characteristics
Particle Size
Particle Size Distribution
Explosive properties

No data available

No information available No information available No information available

9.2. Other information

No information available

9.2.1. Information with regard to physical hazard classes No information available Oxidizing properties

None

9.2.2. Other safety characteristics No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity	
Reactivity	No data available.
10.2. Chemical stability	
Stability	Stable under normal conditions.
Explosion data	
Sensitivity to Mechanical Impact	No data available.
Sensitivity to Static Discharge	No data available.

10.3. Possibility of hazardous reactionsPossibility of hazardous reactions10.4. Conditions to avoidConditions to avoidNone known.

10.5. Incompatible materialsNone known.

10.6. Hazardous decomposition products

Hazardous decomposition products Thermal decomposition products include oxides of nitrogen, carbon monoxide, carbon dioxide, and halogen containing gases.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information:	The information included in this section describes the potential hazards of the individual ingredients
Known Clinical Effects:	The most common adverse effects seen during clinical use of this drug include increase in blood pressure (hypertension), nausea, vomiting, irregular heartbeat (cardiac arrhythmia), increased heart rate (tachycardia); respiratory arrest, troubled breathing.
Acute toxicity	Based on available data, the classification criteria are not met.
Serious eye damage/eye irritation	Based on available data, the classification criteria are not met.
Skin corrosion/irritation	Based on available data, the classification criteria are not met.
Respiratory or skin sensitization	Based on available data, the classification criteria are not met.
STOT - single exposure	Based on available data, the classification criteria are not met.
STOT - repeated exposure	Based on available data, the classification criteria are not met.
Reproductive toxicity	Based on available data, the classification criteria are not met.
Germ cell mutagenicity	Based on available data, the classification criteria are not met.
Carcinogenicity	Based on available data, the classification criteria are not met.
Aspiration hazard	Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose) SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³ Rat Oral LD 50 3 g/kg Mouse Oral LD 50 4 g/kg Rabbit Dermal LD 50 > 10 g/kg Sodium Acetate Rat Oral LD 50 3500 mg/kg Mouse Oral LD 50 4960 mg/kg Sodium hydroxide Mouse IP LD50 40 mg/kg + ACETIC ACID Mouse Sub-tenon injection (eye) LC 50 5620 ppm/1H Rat Oral LD 50 3310 mg/kg Rabbit Dermal LD 50 1060 uL/kg

	ut/ng		
Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
SODIUM CHLORIDE	= 3 g/kg (Rat)	> 10000 mg/kg (Rabbit)	> 42 mg/L (Rat)1 h
Sodium Acetate	= 3530 mg/kg (Rat)	> 10 g/kg (Rabbit)	> 30 g/m³ (Rat)1 h
Sodium hydroxide	= 325 mg/kg (Rat)	= 1350 mg/kg (Rabbit)	-
+ ACETIC ACID	= 3310 mg/kg(Rat)	= 1060 mg/kg(Rabbit)	= 11.4 mg/L (Rat)4 h

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE Skin irritation Rabbit Mild Eye irritation Rabbit Mild Sodium hydroxide Eye Irritation Rabbit Severe Skin Irritation Rabbit Severe

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s)) <u>Rocuronium Bromide</u> Embryo / Fetal Development Rat Intravenous 0.3 mg/kg NOAEL Not teratogenic Embryo / Fetal Development Rabbit Intravenous 0.02 mg/kg NOAEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result) Rocuronium Bromide Bacterial Mutagenicity (Ames) Negative Chromosome Aberration Human Lymphocytes Negative Micronucleus Rat Bone marrow Negative

Carcinogenicity

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

11.2. Information on other hazards **11.2.1.** Endocrine disrupting properties

Endocrine disrupting properties No information available.

11.2.2. Other information Other adverse effects	No information available.	
Section 12: ECOLOGICAL IN	FORMATION	
Environmental Overview:	Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.	
12.1. Toxicity		
Aquatic Toxicity: (Species, Method, End Point, Duration, Result) + ACETIC ACID Fathead Minnow NPDES LC-50 96 hours 88 mg/L Bluegill Sunfish NPDES LC-50 96 hours 75 mg/L Goldfish NPDES LC-50 24 hours 423 mg/L 12.2. Persistence and degradability		
Persistence and degradability	No information available.	
12.3. Bioaccumulative potential Bioaccumulation	No information available.	
<u>12.4. Mobility in soil</u> Mobility in soil	No information available.	

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
SODIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does
	not apply
Sodium Acetate	The substance is not PBT / vPvB PBT assessment does
	not apply
Sodium hydroxide	The substance is not PBT / vPvB PBT assessment does
	not apply
+ ACETIC ACID	The substance is not PBT / vPvB PBT assessment does
	not apply

12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects

No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Product Name Rocuronium Bromide Injection (Hospira Inc.) Revision date 26-Mar-2023

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number:	Not applicable
UN proper shipping name:	Not applicable
Transport hazard class(es):	Not applicable
Packing group:	Not applicable
Environmental Hazard(s):	Not applicable
Special precautions for user:	Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS AICS	231-791-2 Present
SODIUM CHLORIDE	Flesell
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-598-3
AICS	Present
Rocuronium Bromide	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS Standard for Uniform Schoduling of Medicines and	Schedule 5
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 6
Sodium Acetate	Concoure o
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	204-823-8
AICS	Present
Sodium hydroxide	Net Liste d
CERCLA/SARA Section 313 de minimus % Hazardous Substances RQs	Not Listed 1000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	215-185-5

Product Name Rocuronium Bromide Injection (Hospira Inc.) Revision date 26-Mar-2023

AICS Standard for Uniform Scheduling of Medicines and Poisons (SUSMP) + ACETIC ACID	Present Schedule 5 Schedule 6
CERCLA/SARA Section 313 de minimus % Hazardous Substances RQs California Proposition 65 TSCA EINECS AICS Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Not Listed 5000 lb Not Listed Present 200-580-7 Present Schedule 5 Schedule 6 Schedule 2

Chemical name	French RG number	Title
SODIUM CHLORIDE	RG 78	-
7647-14-5		

European Union

+

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Sodium hydroxide - 1310-73-2	Use restricted. See item 75.	
+ ACETIC ACID - 64-19-7	Use restricted. See item 75.	

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

Chemical name	Plant protection products directive (91/414/EEC)
SODIUM CHLORIDE - 7647-14-5	Plant protection agent
+ ACETIC ACID - 64-19-7	Plant protection agent

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances **AICS** - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of H-Statements referred to under section 3

Flammable liquids-Cat.3; H226 - Flammable liquid and vapor Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage

Data Sources:	Pfizer proprietary drug development information. Publicly available toxicity information.
Reason for revision	Added Pfizer OEL (Section 8). Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information.
Revision date	26-Mar-2023
Prepared By	Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.